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Background: Renal function decline in diabetic kidney disease is accompanied
by calcium and phosphate metabolism alterations. Whereas strontium (Sr2+) has
many similarities with calcium, little is known about Sr2+ in this respect. We
studied the association of plasma Sr2+ concentration and parameters associated
with an altered calcium and phosphate metabolism in diabetic kidney disease.
Materials and methods: Plasma Sr2+ concentration was measured in 450 patients
included in the DIAbetes and LifEstyle Cohort Twente‐1. Patients were
classified based on chronic kidney disease (CKD) stages: stages 1‐2, stage 3 and
stages 4‐5 (estimated glomerular filtration rate of ≥60 mL·min−1·1.73 m−2,
30‐59 mL·min−1·1.73 m−2 and ≤29 mL·min−1·1.73 m−2, respectively). The asso-
ciations between log‐transformed plasma Sr2+ concentration and parameters of
calcium and phosphate metabolism were studied using multivariate linear
regression analysis.
Results: Overall, median plasma Sr2+ concentration was in normal range,
269 nmol/L, but was progressively higher in patients with lower renal function,
that is 246 nmol/L (CKD 1‐2), 347 nmol/L (CKD 3) and 419 nmol/L (CKD 4‐5).
In multivariate analysis, independent associations were found between plasma
Sr2+ concentration and both eGFR (β = −0.401, P < 0.001) and plasma fibroblast
growth factor 23 (FGF23) concentration (β = 0.087, P = 0.04).
Conclusions: We found an independent inverse association between eGFR and
plasma Sr2+ concentration and an independent association between plasma Sr2+
concentration and plasma FGF23 concentration, a marker of deranged calcium
and phosphate metabolism. Further research is needed to determine the mecha-
nisms behind these associations and the impact of an elevation in plasma Sr2+
concentration on bone mineralization and calcification.
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1 | INTRODUCTION
The element strontium (Sr2+) is ranked together with cal-
cium, magnesium and barium in the same column of the
periodic table of the elements and shares major similari-
ties with calcium. First, both elements become available
in the body after absorption in the small intestine and
are transported by similar proteins to be stored in bone
tissue.1-3 Second, calcium and Sr2+ both exit the body
through renal excretion as the main route via a similar
transport pathway.1-4 Finally, Sr2+ has a role analogous
to calcium—albeit weaker—in several physiological pro-
cesses, including blood clotting, muscle contraction and
bone formation.1-3
Food is the main source of Sr2+, especially leafy
vegetables, fruit, seafood, spices and cereals.5 Daily intake
of Sr2+ averages 2 mg, that is considerably lower than
1000‐1500 mg calcium intake. An average person contains
47 μg Sr2+ and 15 g calcium per kilogram body
weight.1,4,6 Although literature is scarce, the normal range
of plasma Sr2+ concentration has been claimed to be
228‐354 nmol/L.5
Little is known on alterations in circulating plasma Sr2+
concentration in patients with renal function impairment.7
Chronic kidney disease (CKD) is accompanied by pro-
nounced changes in calcium and phosphate metabolism.8,9
Some key features are a tendency towards phosphate reten-
tion,10 resulting in an increased secretion of the phospha-
turic peptide hormone fibroblast growth factor 23
(FGF23)11,12 and an increase in plasma parathyroid hor-
mone (PTH) concentrations.13,14 The latter results in
increased bone turnover and therefore stimulates the release
of phosphate and calcium from the bones into the circula-
tion.6,11 As the plasma calcium concentration is under tight
regulation, this increased bone turnover does not result in
hypercalcemia.15
It is unknown whether the changes in calcium and
phosphate metabolism associated with progressive CKD
also affect plasma Sr2+ concentrations. Previously, in ani-
mal models with chronic renal failure, signs of increased
Sr2+ concentrations in serum, bone, the liver and the kid-
neys have been reported.16-18 We hypothesize that alter-
ations in mineral metabolism in CKD are associated with
increased plasma Sr2+ concentrations. Whether this subse-
quently results in increased renal excretion to prevent
increased plasma Sr2+ concentrations has not been studied
so far.
Therefore, here we investigate the association between
plasma Sr2+ concentration in diabetic kidney disease and
parameters associated with an altered calcium and phos-
phate metabolism.
2 | MATERIALS AND METHODS
2.1 | Patient inclusion
The study was performed in the DIAbetes and LifEstyle
Cohort Twente‐1 (DIALECT‐1), which was described pre-
viously.19 In short, patients with type 2 diabetes mellitus
(T2DM) aged 18 + years were included, and exclusion cri-
teria were renal replacement therapy or inability to under-
stand the informed consent. Patients were included between
2009 and 2016 in the outpatient clinic of internal medicine/
nephrology in the ZGT Hospital in Almelo and Hengelo.
The study was performed according to the guidelines of
good clinical practice and the Declaration of Helsinki. It
has been approved by the local institutional review boards
(METC registration numbers NL57219.044.16 and
1009.68020) and is registered in the Netherlands Trial
Register (NTR trial code 5855). Prior to participation, all
participants signed an informed consent form.
2.2 | Data collection
Information on medical condition, medication use and
smoking habits were obtained from the electronic patient
records and anamnesis. Information concerning alcohol
consumption was collected through the questionnaire Food
Frequency Questionnaire (FFQ).20 Body dimensions were
measured according to standard procedures. Blood pressure
was measured in a supine position by an automated device
(Dinamap®; GE Medical Systems, Milwaukee, WI, USA)
for 15 minutes with 1‐minute intervals. The mean systolic
and diastolic pressure of the last three measurements was
used for further analysis. Blood samples were taken by
venipuncture. In addition, every patient collected 24‐hour
urine. Samples of blood and 24‐hours urine were stored for
later analysis. Unless noted otherwise, all analyses were
performed using routine laboratory procedures. Notably,
PTH was analysed using a second‐generation immunoassay
(Roche Diagnostics, Indianapolis, Indiana, USA) and
FGF23 by C‐terminal assay (Immutopics, California,
USA).
According to standard practice, plasma calcium concen-
tration was corrected for plasma albumin concentration
with the formula: corrected plasma calcium concentration
(mmol/L) = plasma calcium concentration (mmol/L) + ((40
‐ plasma albumin concentration (g/L))*0.02).
The renal function was estimated by the CKD Epidemi-
ology Collaboration (CKD‐EPI) creatinine‐based formula
for estimation of the glomerular filtration rate (eGFR).21
Albuminuria was defined as urinary albumin excretion
≥ 30 mg/24 h.
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2.3 | Sr2+ measurements
Plasma Sr2+ concentration was determined in stored hep-
arin plasma samples. The samples were diluted 30 times
with 0.5% HNO3 and 0.01% Triton and Rhodium as inter-
nal standard (IS) was added. The samples were analysed
with inductively coupled plasma mass spectrometry (ICP‐
MS), NexION 300D (Perkin Elmer, Massachusetts, USA).
The same technique was applied to determine urinary Sr2+
excretion.
2.4 | Statistical analyses
All statistical analyses were performed using SPSS
statistics 24.0. Variables were tested for normality using
histograms. Normally distributed variables are presented as
the mean and the standard deviation (SD). Skewed vari-
ables are presented as the median and interquartile range
(IQR, 25th‐75th percentile). Binominal variables are dis-
played as number and proportion.
To evaluate Sr2+ levels and components of the calcium
and phosphate metabolism in different stages of CKD, the
study population was divided into three groups according
to CKD stages: CKD stages 1‐2 (eGFR
≥60 mL·min−1·1.73 m−2); CKD stage 3 (eGFR 30‐
59 mL·min−1·1.73 m−2); and CKD stages 4‐5 (eGFR
≤29 mL·min−1·1.73 m−2).20 Differences between the
groups were tested using the one‐way ANOVA (normal
distribution), Kruskal‐Wallis (skewed distribution) and chi‐
square tests. A two‐sided P value <0.05 was considered
statistically significant.
To determine the association between components of
the calcium and phosphate metabolism and plasma Sr2+
concentration, we performed multivariate linear regression
analysis. Plasma Sr2+ concentration was transformed
according to its natural logarithm (LN) to achieve a normal
distribution. We performed partial regression analyses to
account for collinearity. All possible confounders with a P
value <0.1 in univariate analysis were included in the mul-
tivariate linear regression analysis. A backward stepwise
elimination with a threshold on P = 0.05 was used to
select variables in the final model.
3 | RESULTS
3.1 | Study population
A total number of 450 patients, 58% of which were male
were included and the mean age was 63 ± 9 years
(Table 1), and 58% was male. Mean BMI was 33 ± 6 kg/
m2 and in the study population 61% of the patients had a
BMI above 30 kg/m2. Median duration of diabetes was 11
[7‐18] years, and the glucose values of the patients were
tolerably regulated with a mean HbA1c of 57 ± 12 mmol/
mol. The majority used insulin (64%).
Of the study population, 77% had CKD stages 1‐2,
20% had CKD stage 3 and 3% had CKD stages 4‐5.
Mean age of patients with CKD stages 1‐2 was signifi-
cantly lower (61 ± 9 years) than those with the other
CKD stages (68 ± 7 years, P < 0.001 and 69 ± 10 years,
P = 0.007). More patients had albuminuria in CKD stage
3 (47%) and CKD stages 4‐5 (64%) than in CKD stages
1‐2 (25%), P < 0.001. The prevalence of macrovascular
disease was higher in CKD stages 4‐5 (64%) than in
CKD stage 3 (52%) and CKD stages 1‐2 (30%),
P < 0.001.
As expected, the key components of calcium and phos-
phate metabolism differed between CKD stages: plasma
PTH concentration and plasma FGF23 concentration were
significantly higher in each subsequent CKD group
(P < 0.001). Plasma phosphate concentration was highest
in CKD stages 4‐5, although was not significantly different
from the other CKD groups (P = 0.08).
Median plasma Sr2+ concentration was higher in each
subsequent CKD group: 246 [195‐317] nmol/L in CKD
stages 1‐2, 347 [291‐412] nmol/L in CKD stage 3 and
419 [348‐444] nmol/L in CKD stages 4‐5, (P < 0001).
Median urinary Sr2+ excretion was lower in each
subsequent CKD group (P < 0.001). There was an
inverse correlation between eGFR and LN‐transformed
plasma Sr2+ concentration (β = −0.436, P < 0.001;
Figure 1).
3.2 | Relationship between plasma Sr2+
concentration and mineral metabolism
components
To determine the association between plasma Sr2+ con-
centration and components of calcium and phosphate
metabolism, we performed linear regression analysis
(Table 2). Because of high collinearity between individual
components of the calcium and phosphate axis we per-
formed a partial regression analysis (Table S1). All vari-
ables with a P < 0.10 in univariate analysis were
candidates for the multivariate model. Multivariate linear
regression analysis (Table 3) resulted in the following
determinants of the plasma Sr2+ concentration: gender
(β = 0.077, P = 0.064), age (β = −0.082, P = 0.090),
eGFR (β = −0.401, P < 0.001), albuminuria (β = 0.091,
P = 0.034), plasma PTH concentration (β = 0.144,
P = 0.002), in plasma FGF23 concentration (β = 0.087,
P = 0.035), 24‐hours urinary calcium excretion
(β = −0.684, P < 0.001) and in urinary Sr2+ excretion
(β = 0.670, P < 0.001).
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4 | DISCUSSION
We investigated alterations of the plasma Sr2+ concentra-
tion in CKD. In the total study population, the median
plasma Sr2+ concentration was consistent with values
reported in the general population,4 which illustrates that
type 2 diabetes per se is not characterized by increased
plasma Sr2+ concentration. The main finding in this study
was that plasma Sr2+ concentration is progressively
increased according to CKD stage and correlates with com-
ponents of calcium and phosphate metabolism. Plasma Sr2+
concentration reached levels considered as above the nor-
mal range in CKD stages 4‐5.
To the best of our knowledge, the finding that plasma
Sr2+ concentration is higher when renal function is lower
has not been reported previously. The mechanism behind
this association is unclear. Possibly, in patients with CKD,
there is an increased accumulation of plasma Sr2+















Age, years 63 ± 9 61 ± 9 68 ± 7b 69 ± 10a <0.001
Men, n (%) 262 (58) 203 (59) 50 (56) 8 (57) 0.87
Duration diabetes, years 11 [7‐18] 11 [7‐18] 12 [6‐16] 9 [5‐15] 0.62
Plasma HbA1c concentration, mmol/mol 57 ± 12 58 ± 12 56 ± 12 55 ± 14 0.18
Insulin, n (%) 286 (64) 226 (65) 50 (56) 10 (71) 0.19
Macrovascular disease, n (%) 161 (36) 104 (30) 47 (52) 9 (64) <0.001
Body mass index, kg/m2 33 ± 6 33 ± 6 33 ± 6 32 ± 6 0.75
Systolic blood pressure, mm Hg 139 ± 16 140 ± 16 139 ± 16 137 ± 15 0.80
Diastolic blood pressure, mm Hg 76 ± 9 77 ± 9 74 ± 10 74 ± 10 0.07
Smoker, n (%) 75 (17) 57 (17) 16 (18) 2 (14) 0.93
Alcohol, units per month 5 [0‐30] 5 [0‐32] 4 [0‐28] 5 [1‐31] 0.76
RAASi, n (%) 298 (66) 216 (62) 71 (79) 11 (79) 0.01
Vitamin D supplements, n (%) 13 (2.8) 3 (0.9) 5 (5.5) 5 (36) <0.001
Calcium supplements, n (%) 21 (4.7) 18 (5.2) 2 (2.2) 1 (7.1) 0.44
Plasma alkaline phosphatase concentration, U/L 84 ± 29 82 ± 28 86 ± 33 97 ± 32 0.14
Plasma magnesium concentration, mmol/L 0.77 ± 0.09 0.77 ± 0.08 0.77 ± 0.10 0.79 ± 0.12 0.59
Plasma phosphate concentration, mmol/L 0.99 ± 0.18 0.99 ± 0.18 0.98 ± 0.18 1.10 ± 0.34 0.08
Plasma adjusted calcium concentration, mmol/L 2.39 ± 0.10 2.38 ± 0.10 2.39 ± 0.09 2.39 ± 0.11 0.62
Plasma 25 (OH) vitamin D concentration,
nmol/L
42 ± 20 42 ± 19 43 ± 24 46 ± 24 0.65
Plasma PTH concentration, pmol/L 4.00 [3.01‐6.01] 3.60 [2.83‐5.04] 6.03 [4.00‐9.10] 8.44 [6.98‐11.59] <0.001
Plasma FGF23 concentration, RU/mL 95 [70‐142] 84 [66‐117] 143 [104‐203] 229 [140‐662] <0.001
Plasma Sr2+ concentration, nmol/L 269 [207‐355] 246 [195‐317] 347 [291‐412] 419 [348‐444] <0.001
eGFR, mL·min−1·1.73 m−2 84 [62‐97] 90 [77‐99] 44 [37‐54] 27 [21‐28] <0.001
Albuminuria, n (%) 136 (31) 85 (25) 42 (47) 9 (64) <0.001
Urinary albumin excretion, mg/24 h 11 [3‐66] 9 [2‐34] 30 [4‐310] 82 [11‐677] <0.001
Urinary phosphate excretion, mmol/24 h 28 ± 12 29 ± 12 24 ± 8b 22 ± 7 0.001
Urinary calcium excretion, mmol/24 h 3.4 [1.7‐6.2] 4.1 [2.4‐6.8] 1.4 [0.7‐2.3] 0.9 [0.4‐1.4] <0.001
Urinary potassium excretion, mmol/24 h 77 ± 25 79 ± 26 70 ± 21 71 ± 23a 0.007
Urinary sodium excretion, mmol/24 h 186 ± 80 195 ± 81 162 ± 69b 124 ± 52a <0.001
Urinary strontium excretion, nmol/24 h 690 [428‐1023] 784 [512‐1132] 383 [240‐570] 199 [131‐371] <0.001
asignificant difference with ≤90‐60 eGFR mL·min−1·1.73 m−2.
bsignificant difference with ≤90‐60 eGFR mL·min−1·1.73 m−2.
HbA1c, haemoglobin A1c; RAASi, renin‐angiotensin‐aldosterone system inhibitor.
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concentration by reduced renal excretion of Sr2+. In
patients with end‐stage renal disease on haemodialysis,
increased plasma Sr2+ concentration has been interpreted as
a phenomenon of accumulation and may be associated with
an increased risk for development of osteomalacia.16,22-24
From the same point of view, the use of Sr2+ supplements
has been linked with increased risk of Sr2+ accumula-
tion.22-24 The present study shows, however, that increased
plasma Sr2+ concentration in CKD already occurs in the
stages before initiation of dialysis. The hypothesis of Sr2+
accumulation in CKD is supported by our finding that uri-
nary excretion of Sr2+ is decreased in progressive CKD.
We hypothesized that the negative correlation between
plasma Sr2+ concentration and eGFR is associated with the
alterations in calcium and phosphate metabolism and bone
remodelling found in CKD. Therefore, we explored associa-
tions between the plasma Sr2+ concentration and several
variables related to calcium and phosphate metabolism. We
found that plasma FGF23 concentration, which is a marker
of altered calcium and phosphate metabolism in CKD,12 was
correlated with plasma Sr2+ concentration. The associations
of both eGFR and FGF23 with plasma Sr2+ concentration
were independent of other components of calcium and phos-
phate metabolism. Because plasma calcium concentration is
tightly regulated and excess calcium will be periodically
excreted in the urine and faeces,15 increased bone turnover
will not result in hypercalcemia. Sr2 + and calcium both are
transported by similar proteins and are stored in bone tis-
sue.1-3 Given this similarity of calcium and Sr2+, it is likely
that increased bone turnover in CKD increases release of
both calcium and Sr2+ into the circulation. However, we
speculate that, unlike plasma calcium concentrations, plasma
Sr2+ concentration is not tightly regulated and therefore may
increase in circumstances of increased bone turnover.2,3
The independent association between plasma FGF23
concentration and plasma Sr2+ concentration is intriguing.
Over the last decade, FGF23 is increasingly recognized as
a central component in the altered calcium and phosphate
metabolism of CKD12 and a key component already
involved relatively early in the course of the disease.11 The
































β = –0·436, P < 0·001
FIGURE 1 Scatterplot of eGFR vs log‐transformed plasma Sr2+
concentration. There was a statistically significant inverse association
between plasma Sr2+ concentration and eGFR
TABLE 2 Associations between clinical parameters and plasma











Age, years 0.104 0.04
Men, n (%) 0.101 0.04
eGFR, mL·min−1·1.73 m−2 −0.436 <0.001
Duration diabetes, years 0.003 0.96 0.032 0.50
Plasma HbA1c concentration,
mmol/mola
−0.061 0.22 0.007 0.88
Insulin use, n (%) 0.016 0.75 0.050 0.26
Body mass index, kg/m2 0.138 0.005 0.086 0.06
Smoker, n (%) 0.043 0.39 0.053 0.23
Alcohol, units per month 0.009 0.86 0.090 0.07
RAASi, n (%)b 0.128 0.01 0.026 0.57
Vitamin D supplements, n
(%)
0.148 0.003 0.063 0.16
Calcium supplements, n (%) −0.014 0.78 −0.002 0.96
Plasma alkaline phosphatase
concentration, U/L
−0.007 0.88 −0.046 0.31
Plasma magnesium
concentration, mmol/L
−0.047 0.35 −0.060 0.18
Plasma phosphate
concentration, mmol/L
0.098 0.05 0.076 0.09
Plasma adjusted calcium
concentration†, mmol/L
0.021 0.68 −0.002 0.97
Plasma 25 (OH) vitamin D
concentration, nmol/L
−0.126 0.01 −0.142 0.001
Plasma PTH concentration,
pmol/L
0.310 <0.001 0.097 0.06
Ln plasma FGF23
concentration, RU/mL
0.328 <0.001 0.130 0.01
Increased albuminuria, n (%) 0.264 <0.001 0.182 <0.001
Urinary phosphate excretion,
mmol/24 h
−0.091 0.07 0.008 0.87
Urinary calcium excretion,
mmol/24 h
−0.434 <0.001 −0.275 <0.001
Ln urinary strontium
excretion, nmol/24 h
−0.146 0.003 0.155 0.004
aHbA1c is abbreviation of “Glycated Hemoglobin”.
bRAASi is abbreviation of “Renin Angiotensin Aldosterone System inhibitor”.
*Adjusted for age, gender and eGFR.
†Plasma calcium concentration was adjusted for plasma albumin concentration.
HbA1c, haemoglobin A1c; RAASi, renin‐angiotensin‐aldosterone system inhi-
bitor; Ln, natural logarithm.
VAN DEN BERKHOF ET AL. | 5 of 7
changes in FGF23, PTH, phosphate and calcium as found
in the present study are in line with the abundant literature
on CKD.11,14 Given the cross‐sectional nature of our data,
a direct link between Sr2+ and FGF23 cannot be proven
here and would need to be investigated in future studies.
A strength of our study is the fact the study was per-
formed in real‐life setting in a large population of patients
with T2DM. We used only one geographic area, so that the
environmental differences such as the quantity of Sr2+ in
groundwater and air were minimized.25 A limitation of our
study is the cross‐sectional design, allowing only research
of associations and not of causality.
The question that remains is whether high plasma Sr2+
concentration has clinical consequences. Little is known
about Sr2+ and its function in the human body. In previous
trials, low doses of Sr2+ supplementation reduced bone
resorption and increased bone formation in osteoporotic
women.16,26 However, in dialysis patients, an accumulation
of strontium was associated with a higher risk of osteoma-
lacic lesions.16,26 Sr2+ plays the same role as calcium in
bone formation and blood clotting, albeit to a lesser extent.1-
3 It should be kept in mind that plasma Sr2+ concentration is
106 times lower than plasma calcium concentration.1
Besides that, no direct toxic effects of Sr2+ are currently
known.5
However, the possibility exists that Sr2+ plays a role in
the pathophysiology of calcification in blood vessels simi-
lar to calcium: Sr2+ has already been located in aortic valve
plaques.27 Furthermore, the drug Sr2+ ranelate has been
proven to be effective in patients with untreatable osteo-
porosis.26,28 This demonstrates that Sr2+ certainly has some
effect on the bone metabolism. Lastly, plasma Sr2+ concen-
tration could be a potential marker for bone remodelling.
In conclusion, our study revealed an independent
inverse association between eGFR and plasma Sr2+ concen-
tration. Furthermore, we found an independent association
between plasma Sr2+ concentration and plasma FGF23
concentration, a marker of deranged calcium and phosphate
metabolism in CKD. In the total study population, plasma
Sr2+ concentration was within the normal range.
Further research is needed to determine the mechanism
of increased Sr2+ when eGFR is low and to investigate the
impact of increased Sr2+ in bone mineralization and
calcification.
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